Beta
Cabotegravir
medication Under reviewAn integrase strand transfer inhibitor (INSTI) used for the treatment or prevention of HIV-1 infection.
Research summary
Extensive clinical research in healthy, HIV‑negative adults has shown that long‑acting injectable cabotegravir is highly effective for HIV pre‑exposure prophylaxis. Large randomized controlled trials in cisgender men, transgender women, and cisgender women at substantial risk for HIV demonstrated that cabotegravir injections given every 8 weeks reduce HIV acquisition more than standard daily oral tenofovir disoproxil fumarate/emtricitabine. In these trials, both cabotegravir and oral PrEP were highly effective, but cabotegravir showed superior efficacy, in part due to more consistent drug exposure and independence from daily adherence. Safety data from phase 2 and 3 studies indicate that cabotegravir is generally well tolerated in healthy individuals, with injection‑site reactions being the most common adverse effect, usually mild to moderate and decreasing over time. Systemic adverse events are generally similar to placebo or oral PrEP, though there is some signal for modest weight gain and a small risk of developing INSTI‑class resistance in breakthrough infections. Real‑world and implementation studies suggest that persistence and adherence to cabotegravir PrEP are high, supporting its role as a major advance in biomedical HIV prevention rather than as a general health supplement.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Cabotegravir to your stack to report effects
Persistence and Early Implementation Outcomes of Long-Acting Injectable Cabotegravir for HIV PrEP in US Clinical Settings
Doblecki-Lewis S, Kitching G, Park JG, et al.
Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial.
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al.
Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-Uninfected Adults (HPTN 077)
Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, et al.
Reported Side Effects
No reports yet
Be the first to report this effect and help the community.
Add Cabotegravir to your stack to report effects
Persistence and Early Implementation Outcomes of Long-Acting Injectable Cabotegravir for HIV PrEP in US Clinical Settings
Doblecki-Lewis S, Kitching G, Park JG, et al.
Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial.
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al.
Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-Uninfected Adults (HPTN 077)
Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, et al.
No reports yet
Be the first to report this effect and help the community.
Add Cabotegravir to your stack to report effects
Persistence and Early Implementation Outcomes of Long-Acting Injectable Cabotegravir for HIV PrEP in US Clinical Settings
Doblecki-Lewis S, Kitching G, Park JG, et al.
Research (3 studies)
Persistence and Early Implementation Outcomes of Long-Acting Injectable Cabotegravir for HIV PrEP in US Clinical Settings
Doblecki-Lewis S, Kitching G, Park JG, et al.
Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial.
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al.
Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-Uninfected Adults (HPTN 077)
Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!